Mini-review: growth plate senescence, chondrocyte biology and the GH–IGF-1 axis in childhood growth
This mini-review describes local paracrine control of growth-plate cartilage cells, a proposed cell-counting mechanism of growth plate senescence, and mechanism-targeted drugs for achondroplasia; most short stature remains outside this approach. [1]
Automatic summary · not editorially reviewed
The key findings
The review says FGFR3 suppresses chondrocyte proliferation via MAPK/STAT signaling, while the C-type natriuretic peptide/NPR2 pathway counters this by stimulating cGMP. [1]
Growth plate senescence is described as following a proposed localized, cell-counting mechanism reflecting cumulative chondrocyte division, supported by current evidence but not established as the sole explanation for chronological variation in physeal closure. [1]
For achondroplasia specifically, vosoritide, infigretinib and navepegritide are cited as examples of targeting a defined paracrine lesion, producing growth responses that systemic hormone stimulation alone does not achieve in that disorder. [1]
The source at a glance
- Study type / format
- Mini-review (abstract only)
- Population / context
- Children's growth plates and children with short stature, including achondroplasia and a minority of idiopathic short stature cases
- Summary based on
- Study abstract
- Original publication
- October 5, 2026
Local signals controlling chondrocyte proliferation
The review describes the growth plate as actively regulated rather than a passive readout of systemic hormones. It lists local paracrine networks with opposing and cooperating effects: FGFR3 suppresses chondrocyte proliferation through MAPK/STAT signaling, while the C-type natriuretic peptide/NPR2 pathway counters this by stimulating cGMP. The Indian hedgehog–parathyroid hormone-related protein feedback loop, the SHOX gene and mechanical loading add further structural control. Pathogenic variants in these local regulators are linked to achondroplasia and to a minority of cases classified as idiopathic short stature.
Supporting source [1]
Proposed cell-counting senescence and estrogen in puberty
Growth plate senescence is described as following a proposed localized, cell-counting mechanism that reflects cumulative chondrocyte division. The review states that current evidence supports this idea but that it has not been established as the sole explanation for chronological variation in physeal closure. Estrogen is named as a key accelerant of this senescent process during puberty.
Supporting source [1]
Achondroplasia drugs and investigational scope
For achondroplasia specifically, the review cites vosoritide (a C-type natriuretic peptide analog), the FGFR3-directed tyrosine kinase inhibitor infigretinib and the once-weekly CNP prodrug navepegritide as examples of targeting a defined paracrine lesion. Such growth responses, it says, are not achieved by systemic hormone stimulation alone in that disorder. For a limited group of monogenic growth-plate disorders, mechanism-based therapy is beginning to complement uniform systemic intervention, but this paradigm remains investigational for the great majority of children with short stature.
Supporting source [1]
How to interpret this
This is an abstract of a mini-review; the full text was not reviewed. The cell-counting mechanism is proposed and not established as the sole explanation. Mechanism-based therapy remains investigational for the great majority of children with short stature.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Soliman AT, Alyafei F, Alaaraj N, Hamed N, Ahmed S. · europepmc.org · October 5, 2026